Boehringer Ingelheim Patent-Cliff Exposure & CMS Drug Spending Portfolio
Boehringer Ingelheim (Ridgefield, CT): 41 reconciled FDA prescription therapies (83.8% 2025 to 2030 cliff risk), $21.55B 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Ridgefield, CT |
| Reconciled FDA Portfolio Therapies | 41 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 83.8% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $21.55B |
| 2024 Medicare Part D Spend | $18.14B |
| 2024 Medicaid Spend | $3.40B |
| California HCAI SB 17 Filings | 10 WAC filings (max 19.2% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.